Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in two upcoming investor conferences in March 2025.

The company will attend the TD Cowen 45th Annual Health Care Conference in Boston, with a fireside chat scheduled for March 3, 2025, at 1:50 p.m. ET. Additionally, Voyager will participate in the Stifel 2025 Virtual CNS Forum, featuring a fireside chat on March 19, 2025, at 11:00 a.m. ET.

Webcasts of both presentations will be available through the Investors section of Voyager's website at ir.voyagertherapeutics.com. Interested parties can access replays of the webcasts, which will remain archived on the company's website for a minimum of 30 days after the events.

LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences:

• TD Cowen 45^th Annual Health Care Conference, in Boston, including a fireside chat at 1:50 p.m. ET on March 3, 2025
• Stifel 2025 Virtual CNS Forum, including a fireside chat at 11:00 a.m. ET on March 19, 2025

Webcasts of the presentations will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcasts will be archived on the Company’s website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Contacts

Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Mike Hencke, mhencke@kendallir.com  
Media: Brooke Shenkin, brooke@scientpr.com

FAQ

When is Voyager Therapeutics (VYGR) presenting at the TD Cowen Health Care Conference?

Voyager Therapeutics will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 1:50 p.m. ET.

What investor conferences will VYGR attend in March 2025?

VYGR will attend two investor conferences in March 2025: the TD Cowen 45th Annual Health Care Conference in Boston on March 3, and the Stifel 2025 Virtual CNS Forum on March 19.

How can investors access Voyager Therapeutics' (VYGR) conference presentations?

Investors can access webcasts of VYGR's presentations through the Investors section of the company's website at ir.voyagertherapeutics.com.

How long will VYGR's conference webcasts be available for replay?

Replays of Voyager Therapeutics' conference webcasts will be archived on the company's website for at least 30 days after the events.

What time is Voyager Therapeutics presenting at the Stifel 2025 Virtual CNS Forum?

Voyager Therapeutics (VYGR) will present at the Stifel 2025 Virtual CNS Forum on March 19, 2025, at 11:00 a.m. ET.